Table 2.

Adjusted and PS-matched risk of 30-day all-cause hospitalization or facility-reported mortality

Outcome	High risk Sotrovimab, no. (%), N = 15,633	High risk No mAb, no. (%) N = 1,514,868	RRa,b (95% CI)	PS matched RRa,c (95% CI)	P-valued
30-day hospitalization	418 (2.67)	84,307 (5.57)	0.45 (0.41, 0.49)	0.39 (0.36, 0.43)	< 0.001
30-day mortality	13 (0.08)	8167 (0.54)	0.15 (0.08, 0.29)	0.12 (0.06, 0.24)	< 0.001
30-day hospitalization or mortality	419 (2.68)	84,720 (5.59)	0.45 (0.41, 0.49)	0.39 (0.35, 0.43)	< 0.001

PS propensity score, mAb monoclonal antibody, RR relative risk, CI confidence interval

^aReference group = high-risk no mAb

^bAdjusted for diagnosis month category, age, gender, region, rurality, high-risk conditions, and documented COVID-19 vaccine

^c15,633 sotrovimab patients were matched with 62,532 no mAb patients on diagnosis month, age, gender, region, rurality, and selected high-risk conditions

^dP-value applies to RR and PS-matched RR